Checkpoint Blockade + Chemotherapy: the Right Combination for AML?

An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved...

Full description

Saved in:
Bibliographic Details
Published inBlood cancer discovery Vol. 2; no. 6; pp. 551 - 554
Main Authors Wei, Spencer C, Mancuso, James J, Daver, Naval, Allison, James P
Format Journal Article
LanguageEnglish
Published United States American Association for Cancer Research 01.11.2021
Subjects
In the Spotlight
Online AccessGet full text

Cover

More Information
Summary:An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved mechanism-based design of combination therapies to maximum efficacy and minimum toxicity. .
Bibliography:Blood Cancer Discov 2021;2:551–4
ISSN:2643-3230
2643-3249
DOI:10.1158/2643-3230.BCD-21-0130